Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir

Executive Summary

In what is poised to be one of the biggest marketing battles of the year, as Merck's Victrelis (boceprevir) and Vertex's Incivek (telaprevir) close in upon approval, how FDA handles different subgroups of hepatitis C patients in labeling for each of the protease inhibitors could be a determining factor.

You may also be interested in...

Janssen’s Simeprevir May Require Hep C Subpopulation Screening

FDA advisory committee briefing documents recommend patients be screened for the Q80K polymorphism because of lower efficacy in those patients, an issue not seen with Incivek or Victrelis.

Interferon-Free Hepatitis C Regimens Within Reach

Much of the hep C wish list was on display at the American Association for the Study of Liver Disease meeting in Boston Nov. 10-13 – all-oral interferon-free drug combinations for hepatitis C, regimens that don’t require ribavirin, and the possibility of a one-pill, once-a-day cure – demonstrating the Gold Rush mentality in the hep C space as drug makers race to put the pieces together and grab a share of a burgeoning market.

Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week

Merck will begin shipping Victrelis (boceprevir) to pharmacies within a week, the company announced following FDA approval of the hepatitis C drug after market-close on May 13 – a time-frame that roughly coincides with expected FDA action on Vertex's Incivek (telaprevir).

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts